Camrelizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD1 |
| Clinical data | |
| Other names | SHR-1210 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Camrelizumab (SHR-1210) (INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2] PD-1 is programmed cell death protein 1.
The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019[update], camrelizumab is undergoing Phase II/III trials.
References
[edit]- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
- ^ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi:10.1200/JCO.18.02151. PMID 31039052. S2CID 141482897.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |